查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2024425

生物標記市場報告：按產品、類型、疾病、應用、最終用戶和地區分類（2026-2034 年）

Biomarkers Market Report by Product, Type, Disease, Application, End User, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 139 Pages | 商品交期: 2-3個工作天內

價格

2025年全球生物標記市場規模達991億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到2,538億美元，2026年至2034年的複合年成長率（CAGR）為10.58%。目前，北美市場佔據主導地位，這主要得益於該地區主要市場參與者的存在以及有利的監管政策。推動市場成長的關鍵因素包括慢性病盛行率的上升、生物技術和基因組學的持續進步、個人化醫療的興起、分析技術的不斷改進，以及醫護人員和患者對生物標記益處的認知不斷提高。

市場規模及預測：

  • 2025年生物標記市場價值將達到991億美元。
  • 預計從 2026 年到 2034 年，該產業將以 10.58% 的複合年成長率成長，到 2034 年達到 2,538 億美元。

主要部分：

  • 產品：隨著腫瘤學、心臟病學和神經科學等各個領域生物標記研究的不斷擴展，耗材正在推動市場發展。
  • 類型：安全生物標記佔據最大的市場佔有率，因為FDA和EMA等監管機構強制要求在藥物開發中評估安全生物標記物，以評估潛在的副作用和毒性。
  • 疾病：生物標記在癌症調查、診斷、治療和患者管理中發揮著至關重要的作用，因此腫瘤學領域正在推動市場發展。
  • 應用：生物標記是藥物發現和藥物開發的重要工具，因此藥物發現和藥物開發佔據了最大的市場佔有率。
  • 最終用戶：生物標記對診斷和研究實驗室的運作有重大影響，並服務於廣泛的重要用途，因此診斷和研究實驗室佔據了市場主導地位。
  • 地區：北美是生物標記市場的主要驅動力，這主要得益於癌症、心血管疾病和糖尿病等慢性疾病的高發生率。

市場成長的主要促進因素：

  • 慢性病發生率上升：隨著癌症、心血管疾病和神經退化性疾病等疾病發生率的上升，人們對早期檢測和標靶治療的需求日益成長，而生物標記是其中的關鍵。
  • 個人化醫療的進步：生物標記是製定個人化治療方案的核心，能夠更準確地預測藥物作用和疾病進展，從而推動市場成長。
  • 技術進步——基因組分析、蛋白質體學和高通量篩檢技術——正在顯著改善臨床環境中生物標記的發現、檢驗和利用。
  • 政府和監管措施：除了公共和私營部門的投資外，減少生物標記檢驗的監管障礙正在推動市場擴張，尤其是在腫瘤學和傳染病檢查領域。
  • 製藥業的研發支出：製藥和生技公司增加研發支出，加速了藥物發現、病患分層和臨床試驗最佳化的生物標記發現活動。
  • 伴隨診斷的普及：伴隨診斷擴大使用，它主要依靠生物標記來確定特定治療方法的合適候選人，這正在刺激精準醫療領域的市場。

未來展望：

  • 強勁的成長前景：在診斷領域技術的不斷進步、對精準醫療日益成長的興趣以及在治療領域應用範圍不斷擴大的推動下，診斷生物標記市場預計將實現強勁且持續的成長。
  • 市場轉型：市場將從僅限於研究目的轉向更廣泛的臨床應用，生物標記將成為全球醫療保健系統中標準診斷、治療方法選擇和疾病監測的重要組成部分。

生物標記市場的成長受多種關鍵因素驅動。基因組學、蛋白質組學、轉錄組學和代謝體學技術的進步不斷革新著生物標記的發現和應用。科學家正利用次世代定序（NGS）、質譜和生物資訊學等技術，以更高的精確度和準確度識別新的生物標記。這些技術進步加深了我們對疾病機制和生物路徑的理解。因此，製藥公司正致力於開發更具標靶性的治療方法，診斷設備製造商也正在建立更具標靶性的檢測平台。大學和研發實驗室正與技術供應商合作，協同利用這些創新成果。

生物標記市場趨勢及促進因素：

疾病負擔加重和醫療保健支出增加

生物標記領域最重要的促進因素之一是全球疾病負擔的日益加重，尤其是癌症、心血管疾病和糖尿病等慢性疾病。預計到2025年，美國將新增2,041,910例癌症病例和618,120例癌症相關死亡病例。生物標記對於疾病的早期發現、診斷和後續觀察至關重要。這使得臨床醫生能夠更有效地評估疾病風險、制定治療方案並監測治療效果。隨著醫療保健系統努力應對日益成長的疾病負擔，生物標記成為透過早期療育和標靶治療改善患者預後和降低醫療成本的重要工具。慢性疾病負擔的持續加重正在顯著影響生物標記市場的價值，凸顯了生物標記在疾病的早期發現、診斷和監測中發揮的關鍵作用，從而改善患者預後並降低醫療成本。

生物技術領域的顯著進展

基因組學、蛋白質組學和高通量篩檢等生物技術工具和技術的不斷發展，徹底改變了生物標記的發現和檢驗過程。因此，人們不斷發現具有高靈敏度和特異性的新型生物標記物，進一步提升了其在診斷和預後預測方面的潛力。此外，個人化醫療的興起高度依賴生物標記，以便根據患者的個別特徵最佳化治療方案。基於生物標記的策略使醫療專業人員能夠選擇最合適的治療方法，最大限度地提高療效並減少副作用。這不僅改善了患者照護，也增加了對基於生物標記的治療方法和檢測的需求。根據IMARC Group預測，到2033年，生技市場規模預計將達到13,159億美元。

藥物研發和臨床試驗增加

生物標記在藥物發現和開發產業的重要性日益凸顯，正加速並成為藥物研發的主要動力。生物標記能夠辨識標靶、在臨床試驗中進行患者分層，並評估藥物的療效和安全性。這有助於提高藥物研發效率、降低成本，並提高新藥上市的成功率。監管機構也日益認知到生物標記在藥物核准中的重要性，這進一步加速了其在臨床試驗和藥物開發平臺中的應用。生物標記市場的機會在於開發能夠滿足日益成長的個人化醫療和標靶治療需求的先進生物標記物，從而提高診斷準確性和治療效果。 2024年，美國衛生與公眾服務部 (HHS) 下屬的美國衛生高級研究計畫署 (ARPA-H) 宣布透過眼科生物標記分析實驗室 (OCULAB) 計畫提供新的資助機會。 OCULAB 旨在建立一個基於淚液的生物標記測量系統，該系統將放置在淚管中，用於持續的健康評估，並透過封閉回路型給藥機制實現高度精確的藥物輸送，從而進行個人化治療。

生物標記市場成長要素：

對個人化醫療（精準醫療）的需求日益成長

個人化醫療的興起正在從根本上改變醫療保健的實踐方式，也是生物標記市場最強勁的驅動力之一。傳統的「一刀切」式治療方法往往導致療效不佳、不必要的副作用以及醫療成本增加。個人化醫療透過根據每位患者的獨特特徵（包括基因譜、分子指紋、生活方式和環境）量身定做醫療方案來解決這些問題。而生物標記正是其核心。生物標記能夠根據患者對特定治療方法的預測反應進行分組。這使得醫療專業人員能夠選擇最佳治療方法，同時避免使用療效甚微甚至無效的藥物，或可能有害的藥物。例如，在腫瘤學領域，乳癌的HER2和肺癌中的EGFR突變等生物標記能夠幫助腫瘤科醫師判斷患者是否適合接受標靶治療。此外，生物標記也有助於預測藥物反應和評估治療效果。它們還能指導劑量最佳化，在最大限度地降低副作用風險的同時，給予患者最有效的劑量。這不僅可以改善臨床療效，還可以提高治療的成本效益。

「體學」技術領域的技術創新

生物標記發現領域得益於體學技術的創新，特別是基因組學、蛋白質組學、代謝體學和轉錄組學的進步，取得了顯著進展。這些高通量研究領域能夠深入了解疾病的分子基礎，使科學家能夠以前所未有的深度和精確度發現新的生物標記。次世代定序（NGS）技術的突破性進展使得快速定序整個基因組和EXOME組成為可能，同時成本也逐漸降低。這使得識別與疾病易感性、進展和治療反應相關的遺傳變異成為可能。質譜等技術提高了檢測和定量蛋白質及其轉譯後修飾的能力。這對於識別可用於診斷和預後的蛋白質生物標記至關重要。代謝體學和轉錄組學分別測量代謝譜和RNA表達水平，捕捉細胞在特定時間點的行為簡介。這些方法對於理解疾病動態和尋找生理變化的早期標記物正變得至關重要。此外，計算生物學和生物資訊學的日益強大，使研究人員能夠準確地解讀和管理複雜的體學資料集。透過整合多體學策略，生物標記的發現正在催生出更強效、更具臨床意義的生物標記。

人工智慧（AI）與機器學習（ML）的融合

透過體學技術和臨床試驗獲得的大量生物數據正在推動對下一代分析工具的需求。人工智慧 (AI) 和機器學習 (ML) 正在成為生物標記科學領域的革命性驅動力，顯著提升了發現和檢驗流程的速度、準確性和擴充性。 AI 和 ML 演算法能夠處理遠超人類能力的大量複雜資料集，並揭示基因表現、蛋白質-蛋白質相互作用和臨床反應中的潛在模式。例如，在癌症診斷中，機器學習模型正被訓練用於檢測細微的分子特徵，在症狀出現之前預測腫瘤的發展。在神經退化性疾病，AI 正在幫助人們發現能夠透過穿戴式裝置和腦部影像預測認知衰退的數位生物標記。 AI 平台也被應用於藥物研發。製藥公司正在利用 ML 模型對臨床試驗中的生物標記候選物進行排序，從而縮短研發時間並降低成本。這些工具改善了臨床試驗設計，幫助研究人員選擇合適的患者群體，並更有效地評估治療效果。此外，隨著醫療系統採用電子健康記錄 (EHR) 並整合真實世界數據 (RWD)，人工智慧和機器學習正被用於資料挖掘，以獲取可操作的生物標記資訊。這種整合正在為更個人化、數據驅動和預防性的醫療服務鋪平道路。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球生物標記市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依產品分類

  • 消耗品
  • 服務
  • 軟體

第7章 市場區隔：依類型

  • 療效生物標記
  • 安全生物標記
  • 檢驗生物標記

第8章 市場區隔：依疾病分類

  • 癌症
  • 心血管疾病
  • 神經系統疾病
  • 免疫系統疾病
  • 腎臟疾病
  • 其他

第9章 市場區隔：依應用領域分類

  • 診斷
  • 藥物發現與開發
  • 個人化醫療
  • 其他

第10章 市場區隔：依最終用戶分類

  • 製藥和生物技術公司
  • 診斷與研究實驗室
  • 醫院和專科診所
  • 其他

第11章 市場區隔：按地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第12章 SWOT 分析

第13章：價值鏈分析

第14章：波特五力分析

第15章：價格分析

第16章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Abbott Laboratories
    • Agilent Technologies, Inc.
    • Axon Medchem
    • bioMerieux
    • Bio-Rad Laboratories, Inc.
    • Centogene GmbH
    • Charles River Laboratories International, Inc.
    • Myriad Genetics, Inc.
    • Sino Biological, Inc.
    • SphingoTec GmbH
    • Thermo Fisher Scientific Inc.
Product Code: SR112026A6320

The global biomarkers market size reached USD 99.1 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 253.8 Billion by 2034, exhibiting a growth rate (CAGR) of 10.58% during 2026-2034. At present, North America dominates the market, attributed to the presence of key market players and favorable regulatory policies. The rising prevalence of chronic diseases, ongoing developments in biotechnology and genomics, the shift toward personalized medicine, continuous advancements in analytical technologies, and increasing awareness among both healthcare professionals and patients about the benefits of biomarkers are some of the major factors propelling the market.

MARKET SIZE & FORECASTS:

  • Biomarkers market was valued at USD 99.1 Billion in 2025.
  • The market is projected to reach USD 253.8 Billion by 2034, at a CAGR of 10.58% from 2026-2034.

DOMINANT SEGMENTS:

  • Product: Consumables dominate the market driven by continuous expansion of biomarker research in various fields, including oncology, cardiology, and neuroscience, necessitates.
  • Type: Safety biomarkers hold the largest share in the market as regulatory agencies, such as the FDA and EMA, mandate the evaluation of safety biomarkers in drug development to assess potential adverse effects and toxicity.
  • Disease: Cancer dominates the market as biomarkers play a pivotal role in cancer research, diagnosis, treatment, and patient management.
  • Application: Drug discovery and development hold the largest share in the market as biomarkers are indispensable tools in drug discovery and development.
  • End User: Diagnostic and research laboratories dominate the market since biomarkers have a significant impact on the operations of diagnostic and research laboratories, serving a wide range of crucial purposes.
  • Region: North America leads the biomarkers market driven high prevalence of chronic diseases, including cancer, cardiovascular disorders, and diabetes.

KEY PLAYERS:

  • The leading companies in the market include Abbott Laboratories, Agilent Technologies, Inc., Axon Medchem, bioMerieux, Bio-Rad Laboratories, Inc., Centogene GmbH, Charles River Laboratories International, Inc., Myriad Genetics, Inc., Sino Biological, Inc., SphingoTec GmbH, Thermo Fisher Scientific Inc., etc.

KEY DRIVERS OF MARKET GROWTH:

  • Increased Incidence of Chronic Diseases: The increasing incidence of diseases like cancer, cardiovascular diseases, and neurodegenerative disorders is leading to increased demand for the early detection and focused therapies, where biomarkers are the key.
  • Advances in Personalized Medicine: Biomarkers are at the core of the formation of personalized therapeutic regimens, allowing for better predictions of drug action and disease course, thus fueling the market growth.
  • Technological Advancements: Genomic, proteomic, and high-throughput screening technologies are greatly improving the discovery, validation, and use of biomarkers in the clinical environment.
  • Government and Regulatory Initiatives: Public and private sector investment, as well as reduced regulatory hurdles for biomarker validation, are driving the market expansion, particularly in the areas of oncology and infectious disease testing.
  • Research Expenditures in Pharma: Rising research and development expenditure by pharmaceutical and biotechnology firms is accelerating biomarker discovery activities for drug development, patient stratification, and clinical trial optimization.
  • Companion Diagnostic Adoption: The expanding adoption of companion diagnostics that depend significantly on biomarkers to determine appropriate candidates for particular treatments is enhancing the market in precision medicine applications.

FUTURE OUTLOOK:

  • Strong Growth Outlook: The market for diagnostic biomarkers is anticipated to register robust and sustained growth as a result of ongoing technology advancements in the field of diagnosis, growing interest in precision medicine, and widening applications to therapeutic classes.
  • Market Evolution: The market will transform from research use limitations to extensive clinical use, where biomarkers will be an essential part of standard diagnostics, treatment choices, and monitoring disease in global healthcare systems.

The biomarkers market growth is driven by several crucial factors. Advancing genomic, proteomic, transcriptomic, and metabolomic technologies are continually revolutionizing the discovery and use of biomarkers. Scientists are utilizing next-generation sequencing (NGS), mass spectrometry, and bioinformatics to identify new biomarkers more precisely and accurately. These technological advances are facilitating greater insights into the mechanisms of disease and biological pathways. Pharmaceutical firms are consequently working on more targeted therapies, and diagnostic manufacturers are creating more targeted testing platforms. Universities and research and development (R&D) laboratories are teaming up with technology suppliers to leverage these innovations synergistically.

BIOMARKERS MARKET TRENDS/DRIVERS:

Increasing disease burden and healthcare expenditure

One of the most major drivers of the biomarkers sector is the increasing worldwide disease burden, most notably chronic diseases such as cancer, cardiovascular diseases, and diabetes. In 2025, it is estimated that there will be 2,041,910 newly diagnosed cancer cases and 618,120 cancer-related deaths in the United States. Biomarkers are critical in the early detection, diagnosis, and monitoring of diseases. They allow clinicians to diagnose disease risks, design treatment plans, and monitor response to therapy more effectively. While healthcare systems struggle to cope with these mounting disease burdens, biomarkers present an essential aid in enhancing patient outcomes and lowering healthcare expenditure through early intervention and focused treatment. The rising worldwide burden of chronic diseases places its stamp on the biomarkers market value, highlighting the pivotal role of biomarkers in earlier disease detection, diagnosis, and monitoring to achieve better patient outcomes and lower costs of healthcare.

Notable breakthroughs in biotechnology

The ongoing evolution of biotechnological tools and methods, such as genomics, proteomics, and high-throughput screening, has turned the process of biomarker discovery and validation around. This has resulted in the discovery of new biomarkers with high sensitivity and specificity, which further boosts their diagnostic and prognostic potential. Additionally, the shift toward personalized medicines is heavily dependent on biomarkers for optimizing the treatments according to individual patient profiles. Biomarker-guided strategies allow healthcare professionals to choose the most appropriate therapies, thus maximizing the efficacy of treatment and reducing side effects. This has not only enhanced patient care but also enhanced the need for biomarker-based therapeutics and tests. The IMARC Group predicts that the biotechnology market is anticipated to reach USD 1,315.9 Billion by 2033.

Increased drug discovery and clinical trials

Biomarkers are increasingly becoming crucial in the drug discovery and development industry, which is fueling drug development, and hence proving to be a foremost growth driver. They enable target identification, stratification of patients for clinical trials, and drug efficacy and safety assessment. This leads to efficient drug development processes, lower costs, and improved success rates for launching new drugs. Regulatory authorities increasingly identify the importance of biomarkers in drug approval, which is further enhancing their adoption into clinical trials and drug development pipelines. The opportunity in the biomarkers market is the creation of advanced biomarkers that align with increasing need for personalized medicine and targeted treatments, improving diagnostic precision and treatment effectiveness. In 2024, The Advanced Research Projects Agency for Health (ARPA-H), part of the U.S. Department of Health and Human Services (HHS), revealed a new funding opportunity via the Ocular Laboratory for Analysis of Biomarkers (OCULAB) program. OCULAB aims to create a biomarker measurement system using tears that can be placed in the tear duct for ongoing health assessment and enable highly accurate medication dosing for individualized treatment through a closed-loop delivery mechanism.

BIOMARKERS MARKET GROWTH DRIVERS:

Increasing Need for Personalized Medicine (Precision Medicine)

The growing shift towards personalized medicine is essentially changing the face of healthcare, making it one of the strongest drivers for the biomarkers market. Conventional "one-size-fits-all" treatment methodologies tend to lead to suboptimal results, wasteful side effects, and augmented healthcare expenditure. Personalized medicine rectifies this by individualizing medical treatment to the unique features of each patient, such as their genetic profile, molecular fingerprint, lifestyle, and environment. Biomarkers lie at the centre of it all. They make the division of patients into groups based on how they will likely respond to a particular therapy possible. It assists practitioners in choosing the best therapy while eschewing drugs with little or no hope of success or that could be harmful. For instance, in oncology, biomarkers such as HER2 in breast cancer or EGFR mutation in lung cancer enable oncologists to ascertain if a patient is eligible for targeted treatments. Additionally, biomarkers help in anticipating drug response and evaluating the effectiveness of treatment. They also inform the process of dose optimization, which ensures the administration of the most effective dose with least risk of side effects. This not only enhances clinical outcomes but also improves the cost-effectiveness of therapies.

Technological Innovations in 'Omics' Technologies

The sector of biomarker discovery has been profoundly advanced by innovation in omics technologies, specifically genomics, proteomics, metabolomics, and transcriptomics. These high-throughput research areas are providing detailed insights into the molecular basis of disease, enabling scientists to discover new biomarkers with unprecendented depth and precision. Breakthroughs in next-generation sequencing (NGS) are making it possible to sequence entire genomes and exomes quickly at progressively decreasing costs. This makes it possible to find genetic variants related to disease susceptibility, progression, and response to treatment. Methods such as mass spectrometry are enhancing the detection and quantitation of proteins and post-translational modifications. This is necessary to identify protein-based biomarkers, which can be applied to diagnosis and prognosis. Metabolomics and transcriptomics measure metabolic profiles and RNA expression levels, respectively, providing a snapshot in time of cellular behavior. They are becoming crucial to understanding the dynamics of disease and finding early markers of change in physiology. Furthermore, computational biology and bioinformatics are becoming increasingly powerful, enabling researchers to accurately interpret and manage omics data sets with many complexities. Biomarker discovery is giving rise to stronger, clinically meaningful biomarkers through the integration of multi-omics strategies.

Convergence of Artificial Intelligence (AI) and Machine Learning (ML)

The deluge of biological data acquired using omics technologies and clinical trials is giving rise to the requirement for next-generation analytical tools. Artificial Intelligence (AI) and Machine Learning (ML) are emerging as revolutionary drivers in biomarker science, accelerating the velocity, precision, and scalability of discovery and validation protocols. AI and ML algorithms can process enormous, intricate datasets well beyond human capabilities. They can also uncovering latent patterns of gene expression, protein interactions, and clinical response. For example, in cancer diagnosis, ML models are being trained to detect subtle molecular signatures that can predict the occurrence of tumors even before the onset of symptoms. In neurodegenerative disorders, AI is assisting in finding digital biomarkers on wearable devices and brain imaging that can predict cognitive decline. AI platforms are also being applied in pharmaceutical development. Pharmaceutical organizations are leveraging ML models to rank biomarker candidates for clinical trials, cutting the time and cost of development. Such tools are enhancing clinical trial design, assisting researchers in choosing the right patient populations and measuring therapeutic efficacy more effectively. In addition, as healthcare systems implement electronic health records (EHRs) and incorporate real-world data (RWD), AI and ML are being used more and more to mine the data for actionable biomarker insights. This integration is paving the way for more personalized, data-driven, and proactive care.

BIOMARKERS INDUSTRY SEGMENTATION:

Breakup by Product:

  • Consumables
  • Services
  • Software

Consumables dominate the market

The demand for consumables in the biomarkers market is driven by several influential factors. Primarily, the continuous expansion of biomarker research in various fields, including oncology, cardiology, and neuroscience, necessitates a steady supply of consumables. Researchers rely on consumables such as assay kits, reagents, and laboratory supplies to conduct experiments and validate biomarkers for clinical applications. The growing adoption of biomarkers for clinical diagnostics fuels demand for consumables used in diagnostic tests. Consumables like test kits, sample collection devices, and assay reagents are essential for accurate biomarker-based diagnosis, enabling early disease detection and monitoring. Biomarkers are integral to drug discovery and development, where consumables like cell culture media, plates, and assay components are essential. The pharmaceutical industry's robust pipeline of biomarker-driven therapies and the need for large-scale screening drive demand for consumables. The trend towards personalized medicine, which relies on biomarkers for treatment tailoring, has increased the need for consumables. Customized therapies based on individual biomarker profiles require specific consumables for their development and administration.

Breakup by Type:

  • Efficacy Biomarkers
  • Safety Biomarkers
  • Validation Biomarkers

Safety biomarkers hold the largest share in the market

The demand for safety biomarkers in the biomarkers industry is influenced by several critical factors. Regulatory agencies, such as the FDA and EMA, mandate the evaluation of safety biomarkers in drug development to assess potential adverse effects and toxicity. Compliance with these regulations drives the demand for safety biomarker assays and testing services. The high costs associated with drug development, including the expenses incurred due to adverse events and late-stage failures, underscore the importance of safety biomarkers. Early detection of safety concerns can significantly reduce development expenses, prompting the pharmaceutical industry to invest in safety biomarker research and implementation. Ensuring patient safety is paramount in clinical trials. The utilization of safety biomarkers helps identify and mitigate potential risks to participants, aligning with ethical and safety considerations. Technological advancements, such as omics technologies (genomics, proteomics, metabolomics), enable the discovery of novel safety biomarkers with enhanced sensitivity and specificity. The availability of cutting-edge tools and assays drives the adoption of safety biomarkers in drug safety assessment.

Breakup by Disease:

  • Cancer
  • Cardiovascular Disorders
  • Neurological Disorders
  • Immunological Disorders
  • Renal Disorders
  • Others

Cancer dominates the market

Biomarkers play a pivotal role in cancer research, diagnosis, treatment, and patient management. Their applications in cancer are multifaceted and essential. Primarily, biomarkers enable the early detection of cancer, often before symptoms manifest. Blood-based biomarkers, such as circulating tumor DNA (ctDNA) and specific proteins like PSA (Prostate-Specific Antigen), aid in screening and early diagnosis. Biomarkers help confirm cancer diagnoses and classify tumors into specific subtypes. For instance, hormone receptor status (estrogen and progesterone receptors) in breast cancer guides treatment decisions. Biomarkers provide prognostic information, helping predict the course of the disease. Genetic markers and gene expression profiles assist in estimating a patient's likely outcome and risk of recurrence. Biomarkers guide treatment decisions by identifying targeted therapies. For instance, the presence of HER2/neu in breast cancer indicates eligibility for HER2-targeted therapies like trastuzumab. Biomarkers are used to monitor treatment efficacy and disease progression. Imaging biomarkers, like PET scans, assess tumor response to therapy, aiding treatment adjustments.

Breakup by Application:

  • Diagnostics
  • Drug Discovery and Development
  • Personalized Medicine
  • Others

Drug discovery and development hold the largest share in the market

Biomarkers are indispensable tools in drug discovery and development, offering several critical applications that streamline the process and increase its efficiency. Biomarkers help identify and validate potential drug targets by providing insights into their role in disease pathways. This ensures that drug development efforts are focused on biologically relevant targets. Biomarkers aid in assessing the effectiveness of drug candidates during preclinical and clinical trials. They provide quantifiable measurements of the drug's impact on the target and its downstream effects, helping to select the most promising candidates. Safety biomarkers are crucial for evaluating the potential adverse effects of drug candidates. They help identify safety concerns early in the development process, reducing the risk of late-stage failures. Biomarkers enable the stratification of patient populations, identifying subgroups that are more likely to respond to a specific treatment. This supports the development of targeted therapies, optimizing treatment outcomes. Biomarkers play a pivotal role in drug discovery and development, offering indispensable applications that streamline processes and enhance efficiency, as highlighted in the.

Breakup by End User:

  • Pharmaceutical and Biotechnology Companies
  • Diagnostic and Research Laboratories
  • Hospitals and Specialty Clinics
  • Others

Diagnostic and research laboratories dominates the market

Biomarkers have a significant impact on the operations of diagnostic and research laboratories, serving a wide range of crucial purposes. Biomarkers are fundamental in clinical diagnostics, aiding in the accurate and early diagnosis of various diseases. They provide measurable indicators of disease presence or progression, enhancing diagnostic precision. Biomarkers enable the categorization of patients into different risk groups or disease subtypes, helping healthcare providers tailor treatment plans to individual profiles. In research and clinical settings, biomarkers are used to monitor disease progression and assess the effectiveness of treatments. This helps in disease management and optimization of therapeutic interventions. Laboratories use biomarkers to evaluate drug responses, assess drug metabolism, and understand the relationship between drug dose and effect. Biomarkers play a role in assessing the safety of drugs and therapies and identifying potential side effects and toxicities. Biomarkers serve as key tools in laboratory research, aiding in the discovery of new disease mechanisms, drug targets, and potential therapeutic interventions. The indispensable role of biomarkers in diagnostic and research laboratories contributes to the biomarkers market growth, driven by their vital functions in disease diagnosis, treatment tailoring, therapeutic monitoring, and drug development.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Russia
    • Spain
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America exhibits a clear dominance, accounting for the largest market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Russia, Spain, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

The biomarkers industry in North America is driven by several influential factors that contribute to its growth and development. The high prevalence of chronic diseases, including cancer, cardiovascular disorders, and diabetes, in North America has fueled the demand for biomarkers. Biomarkers are crucial for early detection, monitoring, and treatment selection in these conditions. North America boasts a well-developed healthcare infrastructure, including state-of-the-art laboratories and research facilities. This infrastructure supports biomarker research, development, and implementation. The region is home to a robust biotechnology and pharmaceutical industry. Biomarkers play a central role in drug discovery, development, and clinical trials, driving their demand. Regulatory agencies like the FDA in the United States have recognized the importance of biomarkers in drug development and diagnostics. Clear regulatory pathways for biomarker-based products encourage their use. Significant investments in research and development (R&D), both public and private, support biomarker discovery and validation, enhancing their role in healthcare. Ongoing technological advancements in genomics, proteomics, and diagnostic technologies are improving the accuracy and efficiency of biomarker assays.

COMPETITIVE LANDSCAPE:

Key players in the market are actively engaged in various strategic initiatives to advance research, development, and commercialization in this dynamic field. Leading companies invest heavily in R&D to discover and validate novel biomarkers. They collaborate with academic institutions and research organizations to expand their biomarker portfolios. Many biomarker companies form strategic partnerships with pharmaceutical and biotechnology firms to integrate biomarkers into drug development pipelines. These collaborations aim to identify biomarkers for patient stratification and treatment response prediction. Companies continuously expand their biomarker product portfolios, offering a wide range of assays, kits, and services for diverse applications, from diagnostics to drug development. Leading players invest in cutting-edge technologies, such as next-generation sequencing and mass spectrometry, to enhance the sensitivity and specificity of biomarker detection methods. Some key players focus on developing companion diagnostics, and aligning biomarker tests with specific therapies to ensure precise treatment selection and improve patient outcomes.

The market research report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Axon Medchem
  • bioMerieux
  • Bio-Rad Laboratories, Inc.
  • Centogene GmbH
  • Charles River Laboratories International, Inc.
  • Myriad Genetics, Inc.
  • Sino Biological, Inc.
  • SphingoTec GmbH
  • Thermo Fisher Scientific Inc.

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Biomarkers Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Consumables
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Services
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Software
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Type

  • 7.1 Efficacy Biomarkers
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Safety Biomarkers
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Validation Biomarkers
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Disease

  • 8.1 Cancer
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Cardiovascular Disorders
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Neurological Disorders
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Immunological Disorders
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Renal Disorders
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by Application

  • 9.1 Diagnostics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Drug Discovery and Development
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Personalized Medicine
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by End User

  • 10.1 Pharmaceutical and Biotechnology Companies
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Diagnostic and Research Laboratories
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Hospitals and Specialty Clinics
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Others
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia-Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 Abbott Laboratories
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Agilent Technologies, Inc.
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
      • 16.3.2.4 SWOT Analysis
    • 16.3.3 Axon Medchem
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
      • 16.3.3.3 Financials
      • 16.3.3.4 SWOT Analysis
    • 16.3.4 bioMerieux
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
      • 16.3.4.4 SWOT Analysis
    • 16.3.5 Bio-Rad Laboratories, Inc.
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
      • 16.3.5.4 SWOT Analysis
    • 16.3.6 Centogene GmbH
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
      • 16.3.6.4 SWOT Analysis
    • 16.3.7 Charles River Laboratories International, Inc.
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 Financials
      • 16.3.7.4 SWOT Analysis
    • 16.3.8 Myriad Genetics, Inc.
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
      • 16.3.8.4 SWOT Analysis
    • 16.3.9 Sino Biological, Inc.
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
      • 16.3.9.3 Financials
      • 16.3.9.4 SWOT Analysis
    • 16.3.10 SphingoTec GmbH
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
    • 16.3.11 Thermo Fisher Scientific Inc.
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio
      • 16.3.11.3 Financials
      • 16.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Biomarkers Market: Major Drivers and Challenges
  • Figure 2: Global: Biomarkers Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Biomarkers Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Biomarkers Market: Breakup by Product (in %), 2025
  • Figure 5: Global: Biomarkers Market: Breakup by Type (in %), 2025
  • Figure 6: Global: Biomarkers Market: Breakup by Disease (in %), 2025
  • Figure 7: Global: Biomarkers Market: Breakup by Application (in %), 2025
  • Figure 8: Global: Biomarkers Market: Breakup by End User (in %), 2025
  • Figure 9: Global: Biomarkers Market: Breakup by Region (in %), 2025
  • Figure 10: Global: Biomarkers (Consumables) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Biomarkers (Consumables) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Biomarkers (Services) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Biomarkers (Services) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Biomarkers (Software) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Biomarkers (Software) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Biomarkers (Efficacy Biomarkers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Biomarkers (Efficacy Biomarkers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Biomarkers (Safety Biomarkers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Biomarkers (Safety Biomarkers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Biomarkers (Validation Biomarkers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Biomarkers (Validation Biomarkers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Biomarkers (Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Biomarkers (Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Biomarkers (Cardiovascular Disorders) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Biomarkers (Cardiovascular Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Biomarkers (Neurological Disorders) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Biomarkers (Neurological Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Biomarkers (Immunological Disorders) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Biomarkers (Immunological Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Biomarkers (Renal Disorders) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Biomarkers (Renal Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Global: Biomarkers (Other Diseases) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Global: Biomarkers (Other Diseases) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Global: Biomarkers (Diagnostics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Global: Biomarkers (Diagnostics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Global: Biomarkers (Drug Discovery and Development) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Global: Biomarkers (Drug Discovery and Development) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Global: Biomarkers (Personalized Medicine) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Global: Biomarkers (Personalized Medicine) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: Global: Biomarkers (Other Applications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: Global: Biomarkers (Other Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: Global: Biomarkers (Pharmaceutical and Biotechnology Companies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: Global: Biomarkers (Pharmaceutical and Biotechnology Companies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Global: Biomarkers (Diagnostic and Research Laboratories) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Global: Biomarkers (Diagnostic and Research Laboratories) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Global: Biomarkers (Hospitals and Specialty Clinics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Global: Biomarkers (Hospitals and Specialty Clinics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Global: Biomarkers (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Global: Biomarkers (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: North America: Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: North America: Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: United States: Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: United States: Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Canada: Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Canada: Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Asia-Pacific: Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Asia-Pacific: Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: China: Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: China: Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Japan: Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Japan: Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: India: Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: India: Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: South Korea: Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: South Korea: Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Australia: Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Australia: Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Indonesia: Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Indonesia: Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Others: Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Others: Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Europe: Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Europe: Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Germany: Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Germany: Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: France: Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: France: Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: United Kingdom: Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: United Kingdom: Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: Italy: Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 81: Italy: Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 82: Spain: Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 83: Spain: Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 84: Russia: Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 85: Russia: Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 86: Others: Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 87: Others: Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 88: Latin America: Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 89: Latin America: Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 90: Brazil: Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 91: Brazil: Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 92: Mexico: Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 93: Mexico: Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 94: Others: Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 95: Others: Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 96: Middle East and Africa: Biomarkers Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 97: Middle East and Africa: Biomarkers Market: Breakup by Country (in %), 2025
  • Figure 98: Middle East and Africa: Biomarkers Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 99: Global: Biomarkers Industry: SWOT Analysis
  • Figure 100: Global: Biomarkers Industry: Value Chain Analysis
  • Figure 101: Global: Biomarkers Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Biomarkers Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Biomarkers Market Forecast: Breakup by Product (in Million USD), 2026-2034
  • Table 3: Global: Biomarkers Market Forecast: Breakup by Type (in Million USD), 2026-2034
  • Table 4: Global: Biomarkers Market Forecast: Breakup by Disease (in Million USD), 2026-2034
  • Table 5: Global: Biomarkers Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 6: Global: Biomarkers Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 7: Global: Biomarkers Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 8: Global: Biomarkers Market: Competitive Structure
  • Table 9: Global: Biomarkers Market: Key Players